Biomea Fusion, Inc. (BMEA) stock
BMEANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.56−0.05 (-7.89%)
Close on Nov 12, 2026Market cap $40.79MP/E –Yield –
Biomea Fusion operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Biomea Fusion's operating income for the twelve months ending Sep 30, 2026 was -$50.22M. For fiscal 2025 it was -$83.51M. The highest annual figure on record is -$1.20M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$83.51M | – |
| FY2024 | Dec 31, 2024 | -$144.07M | – |
| FY2023 | Dec 31, 2023 | -$126.14M | – |
| FY2022 | Dec 31, 2022 | -$83.63M | – |
| FY2021 | Dec 31, 2021 | -$41.67M | – |
| FY2020 | Dec 31, 2020 | -$5.33M | – |
| FY2019 | Dec 31, 2019 | -$1.20M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$12.96M | – |
| Q2 FY2026 | Jun 30, 2026 | -$12.77M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.77M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.72M | – |
| Q3 FY2025 | Sep 30, 2025 | -$20.81M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.28M | – |
| Q1 FY2025 | Mar 31, 2025 | -$29.71M | – |
| Q4 FY2024 | Dec 31, 2024 | -$30.07M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.04M | – |
| Q2 FY2024 | Jun 30, 2024 | -$38.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$41.06M | – |
| Q4 FY2023 | Dec 31, 2023 | -$37.33M | – |
| Q3 FY2023 | Sep 30, 2023 | -$31.12M | – |
| Q2 FY2023 | Jun 30, 2023 | -$27.66M | – |
| Q1 FY2023 | Mar 31, 2023 | -$30.03M | – |
| Q4 FY2022 | Dec 31, 2022 | -$26.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.48M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.47M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.40M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.74M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.64M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.44M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.86M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.50M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.14M | – |
| Q2 FY2020 | Jun 30, 2020 | -$295.00K | – |
| Q1 FY2020 | Mar 31, 2020 | -$398.00K | – |
See a number that looks wrong?